TherapeuticsMD (TXMD) Total Non-Current Liabilities (2012 - 2026)

TherapeuticsMD's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 9.03% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 9.03% YoY) and the FY2025 annual result came in at $9.9 million, down 7.48% from the prior year.
• Total Non-Current Liabilities was $9.7 million for Q1 2026 at TherapeuticsMD, down from $9.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $272.7 million in Q1 2022 and bottomed at $9.7 million in Q1 2026.
• A 5-year average of $50.6 million and a median of $12.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 90.29% — and 2025, when it declined 7.48%.
• TherapeuticsMD's Total Non-Current Liabilities stood at $54.2 million in 2022, then plunged by 75.31% to $13.4 million in 2023, then dropped by 20.01% to $10.7 million in 2024, then declined by 7.48% to $9.9 million in 2025, then declined by 1.74% to $9.7 million in 2026.
• Business Quant data shows TXMD's Total Non-Current Liabilities at $9.7 million in Q1 2026, $9.9 million in Q4 2025, and $10.4 million in Q3 2025.